Search

Displaying results 2301 - 2310 of 6951 in total
  1. Drug

    Citric acid

    go.drugbank.com/drugs/DB04272
    ApprovedInvestigationalNutraceuticalVet approved

    A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium-chelating ability. Citric acid is one of the active ingredients in Ph...

    Mixtures: Urologic G for Irrigation, Urologic G for IrrigationCategories: Disinfectants (For Agents Used on Object)
  2. Drug

    Sunitinib

    go.drugbank.com/drugs/DB01268
    ApprovedInvestigational

    For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. … On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).

  3. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor], a CFTR potentiator, for

  4. Target

    Human Retinoid X Receptors (RXRs)

    go.drugbank.com/bio_entities/BE0010096
    TargetHumans

    Receptor for retinoic acid. … Receptor for retinoic acid.

    Polypeptides: Retinoic acid receptor RXR-alpha, Retinoic acid receptor RXR-betaSynonyms: Retinoid X receptor alpha, Retinoid X receptor beta
  5. Target

    Peroxisome proliferator-activated receptors

    go.drugbank.com/bio_entities/BE0010120
    TargetHumans and other mammals

    Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. … Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids.

    Polypeptides: Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor deltaSynonyms: Nuclear hormone receptor 1, Nuclear receptor subfamily 1 group C member 1
  6. Drug

    Clomipramine

    go.drugbank.com/drugs/DB01242
    ApprovedInvestigationalVet approved

    See toxicity section below for a complete listing of side effects. … TCAs also block histamine-H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred

    Categories: Antidepressive Agents Indicated for Depression, Serotonin Receptor Antagonists
  7. Drug

    Paltusotine

    go.drugbank.com/drugs/DB16277
    ApprovedInvestigational

    [A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061] … Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth

    Categories: Somatostatin Receptor Agonists
  8. Target

    Prostaglandin E2 Receptors

    go.drugbank.com/bio_entities/BE0010100
    TargetHumans

    Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. … Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system.

    Polypeptides: Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP2 subtypeSynonyms: PGE receptor EP1 subtype, Prostanoid EP1 receptor
  9. Drug

    Nitrogen

    go.drugbank.com/drugs/DB09152
    ApprovedInvestigationalVet approved

    Liquid nitrogen is used principally in cryotherapy for removal of diseased skin.

  10. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. … The presence of the Fc domain extends the terminal half-life which confers clinical benefits of prolonged therapeutic efficacy, less frequent intravenous injections for patient convenience and improved